B. Riley Securities Maintains Buy on Trevi Therapeutics, Raises Price Target to $31

B. Riley Securities analyst Mayank Mamtani maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $21 to $31.